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Abstract  
The tick Ixodes ricinus is widespread along the coastline of southern Norway, but data on 
human exposure to tick-borne microbes are scarce. We aimed to assess the seroprevalence of 
IgG antibodies to various tick-borne microbes in the general adult population living in a 
Norwegian municipality where ticks are abundant. Søgne is a coastline municipality in the 
southernmost part of Norway, and has a high density of ticks.  All individuals aged 18-69 
years with residential address in Søgne municipality (n = 7424) were invited to give a blood 
sample and answer a questionnaire. Blood samples from 3568 individuals were available for 
analysis. All samples were analyzed for IgG antibodies to Borrelia burgdorferi sensu lato 
(Bbsl), and around 1500 samples for IgG antibodies to other tick-borne microbes. Serum IgG 
antibodies to Bbsl was present in 22.0% (785/3568) of the tested samples, tick-borne 
encephalitis virus (TBEV) in 3.1% (45/1453), Anaplasma phagocytophilum in 11.0% 
(159/1452), Babesia microti in 2.1% (33/1537), Bartonella henselae/B. quintana in 0.1% 
(2/1451) and Rickettsia helvetica/R. conorii in 4.2% (60/1445). Serum IgG antibodies to A. 
phagocytophilum and R. helvetica/R. conorii were significantly more prevalent (p = 0.010 and 
p = 0.016, respectively) among individuals with serum IgG antibodies to Bbsl than among 
individuals without. In conclusion, our study showed a high exposure to Bbsl in the general 
adult population living in a coastline municipality in the southernmost part of Norway. The 
population is also exposed to A. phagocytophilum, R. helvetica/R. conorii, B. microti and 
TBEV, but very rarely B. henselae/B. quintana.  
 
 
Human seroprevalence of antibodies to tick-borne microbes in southern Norway 
 
Introduction 
There is an increasing attention to tick-borne infections and their impact on human health. In 
Norway, the tick Ixodes ricinus is widespread along most parts of the southern coastline (Jore 
et al., 2011). Lyme borreliosis caused by Borrelia burgdorferi sensu lato (Bbsl) complex 
species, and tick-borne encephalitis caused by the tick borne encephalitis-virus (TBEV), are 
well-known infections. Erythema migrans, the early local skin infection in Lyme borreliosis, 
is not notifiable to the Norwegian Surveillance System for Communicable Diseases (MSIS), 
but the incidence was estimated to 148/100 000/year in Norway in 2005-2009 (Eliassen et al., 
2017). Disseminated Borrelia infections are notifiable, and the reported incidence was 5.0-
8.2/100 000/year in Norway in 2011-2015 (Ocampo et al., 2016). TBEV infections are also 
notifiable, and the reported incidence was 0.2-0.4/100000/year in Norway in 2011-2015 
(Ocampo et al., 2016). 
 
The last years, several other microbes that may cause human disease, have been detected in 
ticks collected in Norway. These microbes are Anaplasma phagocytophilum, Babesia species, 
Borrelia miyamotoi, Neoehrlichia mikurensis and Rickettsia helvetica (Kjelland et al., 2018; 
Oines et al., 2012; Quarsten et al., 2015). Furthermore, Bartonella species have been detected 
in ticks collected in Denmark (Stensvold et al., 2015). A few cases of human disease caused 
by these so-called novel tick-borne microbes are reported in Norway (Frivik et al., 2017; 
Morch et al., 2015; Stuen and Bergstrom, 2008), but no incidence data exists, and the impact 
of such infections are unknown. 
 
Population-based seroprevalence studies can provide important information about 
epidemiology and diagnostics of tick-borne infections. Firstly, as antibodies generally persist 
in blood for years after symptomatic or asymptomatic infections, the seroprevalence reflects 
cumulative exposure to the various microbes in humans. Secondly, knowledge about the 
background seroprevalence is crucial to correctly interpret an antibody test result in terms of 
diagnostic predictive value.  
 
Routine diagnostics of Lyme borreliosis and other tick-borne infections is mainly based on 
detection of serum antibodies. However, antibody diagnostics is hampered by several factors: 
In early stages of the disease (up to 6-8 wk) antibodies can be absent, the test accuracy is not 
absolute, and antibodies can be present for years after cured infection (Dessau et al., 2018; 
Kalish et al., 2001; Leeflang et al., 2016). It is therefore important that the serological test 
results are interpreted in light of the clinical setting and background seroprevalence in which 
sampling takes place (Dessau et al., 2018). 
 
Several previous studies have assessed seroprevalence of IgG antibodies to Bbsl among blood 
donors from different regions in Norway. The seroprevalence among blood donors was 18.2% 
(45/247) in the south (Vest-Agder county) (Mygland et al., 2006), 9.6% (117/1213) in the 
west (Sogn og Fjordane county) (Hjetland et al., 2014), 9.2% (48/519) in the southeast 
(Vestfold county) and 0.5% (5/1048) in the north (Nordland, Troms and Finnmark counties) 
(Hvidsten et al., 2017). Similar test kit (Enzygnost Lyme link VIsE/IgG) was applied in all 
regions, except in Vest-Agder county (where Premier Human Lyme and Enzygnost Borreliosis 
were applied before and after 1997, respectively). In another Norwegian study of sera from a 
population aged two to > 50 years (in which 74.6% (2280/3057) were < 20 years), the overall 
seroprevalence of antibodies to Bbsl applying two different tests was 2.7% (84/3057) and 
3.4% (104/3057), ranging from 0-7.6% and 1.0-9.6% in different counties (Vestrheim et al., 
2016).  
 
Norwegian seroprevalence data of antibodies to other tick-borne microbes than Bbsl are 
scarce. A few small studies from different parts of the country have assessed seroprevalence 
of IgG antibodies to TBEV, reporting rates at 0% (0/1213) in the west (Sogn og Fjordane 
county), 0.7% (3/461) in the southeast (Østfold county) and 2.4% (3/126) in the south 
(Tromøy, Aust-Agder county) (Hjetland et al., 2015; Larsen et al., 2014; Skarpaas et al., 
2002). The seroprevalence of IgG antibodies to A. phagocytophilum has only been assessed in 
one Norwegian study, and was found to be 16.3% (49/301) among blood donors from western 
Norway (Sogn og Fjordane county) (Hjetland et al., 2015). A study from southern Sweden 
found the seroprevalence of IgG antibodies to Babesia microti/B. divergens to be 2.5% 
(5/197) among healthy individuals and 16.3% (14/86) among individuals seropositive to Bbsl 
antibodies (Svensson et al., 2019). For R. helvetica, two Swedish studies reported 3.8% 
(9/236) and 9.2% (19/206) IgG seropositivity among patients with symptoms of infectious 
disease after a tick-bite, and 0.6% (1/161) and 1.3% (1/80) among healthy control groups 
(Elfving et al., 2008; Lindblom et al., 2013). In another Swedish study among blood donors, 
the seroprevalence of IgG antibodies to two Bartonella henselae strains was 1.2% (6/498) and 
2.0% (10/298), and for Bartinella quintana 0.2% (1/498) (McGill et al., 2005). No studies 
have so far assessed the human seroprevalence of antibodies to Babesia, Bartonella and 
Rickettsia species in Norway. 
 
Most previous studies on seroprevalence of antibodies to tick-borne microbes have been 
restricted to blood donors or other selected population groups, and for several of the “novel” 
tick-borne infections, data on seroprevalence is lacking. In the present study, we therefore 
aimed to assess the seroprevalence of IgG antibodies to various tick-borne microbes in an 
unselected Norwegian adult population living in an area where ticks are abundant.  
 
Material and methods  
Recruitment area  
Søgne is a coastal municipality in Vest-Agder county, in the southernmost part of Norway. 
The municipality has a high density of ticks (Jore et al., 2011). Borrelia burgdorferi sensu 
lato was found in 22.3% of Ixodes ricinus ticks collected in Søgne (Kjelland et al., 2010), and 
the municipality has a high incidence of Lyme neuroborreliosis (19/100,000 annually in 1994-
1999) (Ljostad et al., 2003). In January 2016, there was 11,260 inhabitants in Søgne, of whom 
7,424 were aged from 18 to 69 years (population data from the National Registry). According 
to the MSIS-registry, 0-6 cases of disseminated Lyme borreliosis have been reported annually 




Study participants and recruitment strategies 
All individuals aged 18-69 years, with residential address in Søgne municipality, were invited 
to participate in the study. Participation entailed to give a blood sample and to answer a 
questionnaire. We used two different recruitment strategies; From June 2015 to January 2016, 
eligible individuals who attended the general practitioner’s center were informed about the 
study and invited to participate. Then, from January to June 2016, we sent a letter with study 
information to all eligible individuals not already enrolled in the study and announced that 
they would be contacted by phone within a few weeks. Invitation requests were then made by 
phone, and time for blood sampling agreed. Written informed consent was obtained prior to 
blood sampling and distribution of login key to a web-based questionnaire. Those who did not 
respond to the questionnaire within 2-6 wk after blood sampling were contacted once more by 
letter or phone for a reminder. Recruitment and blood sampling were conducted by Søgne 
medical center, which is the only general practitioner center in the municipality.  
 
Serological tests 
Enzyme-linked immunosorbent assay (ELISA) tests were applied for detection of serum IgG 
antibodies to Bbsl (Enzygnost Lyme link VIsE/IgG, Siemens Healthcare Diagnostics Products 
GmbH, Erlangen, Germany) and TBEV (Serion ELISA classic TBE virus IgG, Institut 
Virion\Serion GmbH, Würzburg, Germany, positive and equivocal results were also 
confirmed with Enzygnost anti-TBE virus IgG, Siemens Healthcare Diagnostics Products 
GmbH). The manufacturer report a specificity at 98-100% for the Enzygnost Lyme link 
VIsE/IgG-test, 90-98% for the Serion ELISA classic TBE virus IgG-test, and 99.5% for the 
Enzygnost anti-TBE virus IgG-test. Confirmation by immunoblot was not performed. 
Classification of sera as negative, equivocal and positive was according to kit instructions. 
Indirect immunofluorescent assay (IFA) tests were used for detection of serum IgG antibodies 
to A.phagocytophilum (Anaplasma phagocytophilum IFA IgG, Focus Diagnostics, Cypress, 
California, USA), B. microti (Babesia microti IFA IgG, Focus Diagnostics), B. henselae/ B. 
quintana (Bartonella IFA IgG, Focus Diagnostics), and R. helvetica/R. conorii (Rickettsia 
Screen IFA IgG Antibody Kit, Fuller Laboratories, Fullerton, California, USA). Because of 
substantial cross reactivity for IgG antibodies to B. henselae/B. quintana and R. helvetica/ R. 
conorii, the results are reported summarized for the Bartonella species and the Rickettsia 
species respectively. All analyses and interpretation of results were performed according to 
the manufacturer's instructions. A sample dilution of 1:64 was applied for evaluation of IFA-
tests. Further titration of positive sera was not performed. All IFA-slides were evaluated 
separately by the same two investigators to ensure equal interpretation. Sera with an IF-
brightness of > 2+ were classified as positive, a score of 1+ to 1.5+ as equivocal. All 3568 
samples were analyzed for Bbsl IgG antibodies. Around 1500 samples were analyzed for IgG 
antibodies to other tick-borne infections, these samples were collected consecutively from the 
start of the study. 
Questionnaire  
Participants were encouraged to answer the questionnaire online, but a paper version was also 
available on request. The questionnaire included questions about demographics, exposure to 
tick-bites, previous tick-borne infections, other diagnoses, regular medication and vaccination 
against tick-borne encephalitis and yellow fever. The web-based questionnaire was designed 
so that each question had to be answered in order to proceed.  
Statistics  
Chi-square/Fisher’s exact test was applied to compare proportions between groups, and 
independent samples t-test to compare mean-values between groups. A p-value <0.05 was 
considered statistically significant. All statistical analyzes were performed using IBM SPSS 
Statistics, version 25 (IBM Corporation, Armonk, New York, USA).  
Ethics  
The study was approved by the Regional Committee for Medical and Health Research Ethics 
(approval number 2013/2082 and 2014/449), and the Research Unit at Sørlandet Hospital. 
Written informed consent was obtained from all participants. Participants could at any time 
withdraw their consent. Seven randomly selected participants received a gift card valued 




Study participants and recruitment rates  
Out of 7424 invited individuals, 3571 responded to the invitation. Serum from 3568 (48.1%) 
individuals were available for analysis, and they were included in the study. Out of the 3568 
included individuals, 1221 (34.2 %) were recruited when visiting the general practitioner’s 
center, 1606 (45.0 %) by invitation letter/phone, and 741 (20.8 %) by other/unknown way of 
recruitment. Recruitment rates according to gender and age groups are described in Table 1. 
Mean age in the study was 48.2 years versus 41.9 years in the whole Søgne population aged 
18-69 years (p < 0.001). The proportion of females was 53.1% in the study versus 48.8% in 
the whole Søgne population aged 18-69 years (p < 0.001). Recruitment rates were lowest 
among younger age groups and males. Out of the 3568 participants, 2968 (83.2%) returned 
the questionnaire.  
 
Self-reported exposure to tick-bites and tick-borne infections  
Reported exposure to tick-bites and tick-borne infections earlier in life are described in Table 
2. More males than females reported at least three tick-bites earlier in life (66.7% vs 61.5%, p 
= 0.003). There were no significant gender differences for reporting at least one tick-bite, nor 
for erythema migrans earlier in life. Five percent (147/2950) reported health complaints 
attributed (by the participant and/or their general practitioner) to tick-borne infection. 
Vaccinations 
Vaccination against TBEV was reported by 4.3% (127/2947) of respondents. For yellow 
fever, 11.7% (344/2944) reported being vaccinated, 37.8% (1113/2944) not being vaccinated, 
and 50.5% (1487/2944) did not know. 
Prevalence of serum IgG antibodies to tick-borne microbes 
The prevalence of serum IgG antibodies to different tick-borne microbes are listed in Table 3. 
All samples were analyzed for serum IgG antibodies to Bbsl, and the prevalence according to 
gender and age groups are listed in Table 4. The prevalence of serum IgG antibodies to Bbsl 
was significantly higher among males than females (27.7% vs 17.0%, p < 0.001), and tended 
for both genders to increase with increasing age. Adjusted for gender and age (based on the 
gender and age stratified seroprevalences listed in Table 4), the estimated overall 
seroprevalence of IgG antibodes to Bbsl in the Søgne population aged 18-69 years was 19.5%. 
The prevalence of serum IgG antibodies to Bbsl in relation to exposure to tick-bites and tick-
borne infections earlier in life as reported by the participants were as follows: No tick-bite, 
13.4% (59/439); one tick-bite, 16.9% (62/366); two tick-bites, 15.8% (41/259); three or more 
tick-bites, 27.2% (513/1883); tick-bite in the last year, 33.1% (326/984); and Bbsl-infection 
earlier in life, 32.1% (244/761). Among participants recruited when attending the general 
practitioner’s center the seroprevalence of IgG antibodies to Bbsl was 21.9% (267/1221), 
whereas among participants recruited by invitation it was 22.9% (367/1606), and among 
participants with other/unknown way of recruitment it was 20.4% (151/741) (p = 0.401). The 
seroprevalence of IgG antibodies to Bbsl was 22.1% (340/1537) among samples tested for at 
least one other tick-borne pathogen, and 21.9% (445/2031) among samples tested only for 
Bbsl (p = 0.880). Among individuals not vaccinated against TBEV and/or yellow fever, the 
seroprevalence of IgG antibodies to TBEV was only 1.4% (6/419). We found no gender 
differences for the seroprevalence of IgG antibodies to TBEV (among individuals not 
vaccinated against TBEV and/or yellow fever), A. phagocytophilum, B. microti, B. 
henselae/B. quintana and R. helvetica/R. conorii. The seroprevalence of IgG antibodies to A. 
phagocytophilum was highest in the age group 60-69 years (16.9%) and lowest in the age 
group 40-49 years (6.7%). There were no differences in seroprevalence of IgG antibodies to 
TBEV (among individuals not vaccinated against TBEV and/or yellow fever), B. microti, B. 
henselae/B. quintana and R. helvetica/R. conorii according to age groups. 
Serum IgG antibodies to A. phagocytophilum and R. helvetica/R. conorii was more prevalent 
among individuals with serum IgG antibodies to Bbsl than among individuals without (p = 
0.010 and p = 0.016, respectively). Serum IgG antibodies to TBEV, B. microti and B. 
henslae/B. quintana did not show significant association with the presence of serum IgG 
antibodies to Bbsl. Among individuals not vaccinated against TBEV and/or yellow fever, the 
seroprevalence of IgG antibodies to TBEV was 2.0% (2/101) among individuals with serum 
IgG antibodies to Bbsl and 1.3% (4/318) among individuals without (p = 0.634).  
Out of 1359 samples tested for all six microbes, 5.5% (75/1359) were seropositive to two 




This is the first large-scale population based study of human exposure to tick-borne microbes 
in Norway. The study participants reported a high exposure to tick-bites; 63.9% reported at 
least three tick-bites earlier in life, and 33.4% reported at least one tick-bite the last year. We 
also found a high seroprevalence of IgG antibodies to Bbsl (22.0%) among the study 
participants. This was within the range reported in a previous study among blood donors 
(18.2%) from the same county (Mygland et al., 2006), but higher than previously found in 
other Norwegian regions (Hjetland et al., 2014; Hvidsten et al., 2017; Vestrheim et al., 2016). 
We did not confirm the results of the ELISA-test by immunoblot because the improvement of 
specificity by two-tier testing is limited (Dessau et al., 2018). However, a slight 
overestimation of the seroprevanence due to lack of confirmation of the positive samples by 
immunoblot, cannot be excluded.  
The seroprevalence of IgG antibodies to Bbsl tended to increase with age (11.9% in the age 
group 18-29 years vs 33.5% in the age group 60-69 years), and was higher among males than 
females (27.7% vs 17.0%, respectively). An increasing seroprevalence with increasing age 
was also found in several previous studies from Norway and other European countries 
(Carlsson et al., 1998; Hjetland et al., 2014; van Beek et al., 2018; Vestrheim et al., 2016; 
Wilking et al., 2015), and is attributed to a cumulative exposure to tick-bites and prolonged 
persistence of serum IgG antibodies after infection. Previous studies from Norway (Hjetland 
et al., 2014; Vestrheim et al., 2016) and other European countries (Carlsson et al., 1998; van 
Beek et al., 2018; Wilking et al., 2015) also report higher seroprevalences of antibodies to 
Bbsl among males than females. This may be due to differences in exposure to tick-bites, or 
immunological factors. More males than females reported exposure to at least three tick-bites 
earlier in life (66.7% vs 61.5%, respectively), but there were no significant gender differences 
regarding reporting at least one tick-bite or tick-borne infection earlier in life. In our study, the 
gender difference in seroprevalence of IgG antibodies to Bbsl therefore seems to be greater 
than the gender difference in reported exposure to tick-bites and tick-borne infections can 
explain. More unnoticed tick-bites among males than females, a tendency that males notice 
and remove ticks later than females (Wilhelmsson et al., 2013), or differences in 
immunological factors, are possible causes for this discrepancy.  
The seroprevalence of IgG antibodies to A.phagocytophilum (11.0%) was lower than 
previously found among blood donors from western Norway (16.3%) (Hjetland et al., 2015), 
but higher than we would expect from a 0-4% prevalence of A. phagocytophilum in ticks from 
our region (Kjelland et al., 2018; Quarsten et al., 2015) and a presumed low transmission rate 
(Henningsson et al., 2015). The cut-off titer recommended by the IFA-test manufacturer (i.e. 
1:64) may also be low, but we did not perform further titration of positive sera as the optimal 
cut-off value is debated (Hjetland et al., 2015). Furthermore, serological reactivity to A. 
phagocytophilum has been reported in 22% (4/18) of patients infected with Neoehrlichia 
mikurensis (Wass et al., 2018), indicating that cross-reactivity may be present. N. mikurensis 
has been detected in 10-19% of ticks collected along the southern coast of Norway (Kjelland 
et al., 2018), in 11% of ticks in northern Norway (Larsson et al., 2018), and in the blood of 
10% of patients (from Aust-Agder and Vest-Agder counties) with erythema migrans or flu-
like symptoms after a tick-bite (Quarsten et al., 2017), but today no commercial serology test 
is available. The seroprevalence of IgG antibodies to R. helvetica/R. conorii (4.2%) was 
higher than reported for R. helvetica among blood donors in Sweden (0.6-1.3%) (Elfving et 
al., 2008; Lindblom et al., 2013), but much lower than among recently tick-bitten individuals 
in Sweden and Åland Islands (44.0%) (Lindblom et al., 2016). Cross-reactivity to other 
Rickettsia species within the spotted-fever group may also be present as the tests have low 
specificity within the Rickettsia spotted-fever group according to the manufacturer’s 
instructions. Seropositivity to A.phagocytophilum and R. helvetica/R. conorii was both 
significantly more prevalent among participants seropositive to Bbsl than among participants 
seronegative to Bbsl, indicating tick-borne transmission of these infections. There was a low 
seroprevalence of IgG antibodies to TBEV, 3.1% among all tested participants and only 1.4% 
among participants reporting no vaccination against TBEV and/or yellow fever. Vaccination 
against Japanese encephalitis was not charted in our questionnaire, but according to the 
Norwegian prescription registry, the number of vaccinations is very low in the area 
(http://reseptregisteret.no). The seroprevalence of IgG antibodies to B. microti was also low 
(2.1%), and in the same range as reported for B. microti/B. divergens among healthy 
individuals in Sweden (2.5%) (Svensson et al., 2019). However, the overall seroprevalence of 
antibodies to Babesia species may be underestimated in our study since the IFA-test applied is 
designed for B. microti, and cross-reactivity for other Babesia species is probably low 
(Lempereur et al., 2015; Sayama et al., 2018). B. microti has not been identified in Norwegian 
ticks (Oines et al., 2012), but was the most prevalent Babesia species in ticks in both a Danish 
and a Swedish study (Karlsson and Andersson, 2016; Stensvold et al., 2015). The Babesia 
species found in the Norwegian study of ticks were B. venatorum, B. divergens and B. 
capreoli (Oines et al., 2012). Tick-borne transmission of Babesia infection may exist in the 
study area, although there was no significant difference in seroprevalence of IgG antibodies to 
B. microti between the Bbsl seropositive and seronegative group. Only two participants 
(0.1%) were seropositive to B. henselae/B. quintana. In a previous study of microbes in ticks 
from the region, Bartonella species was not found (Quarsten et al., 2015), and it was also not 
found in a recent study from Sweden and Åland Islands (Cronhjort et al., 2019). Whether 
other Bartonella species may induce antibodies that cross-react with B. henselae/B. quintana 
is not known. Seropositivity to more than one other tick-borne pathogen than Bbsl was rare. 
The strength of our study is the large number of participants from a general adult population 
in a geographically well-defined area. A weakness of our study is that we have not charted 
travel history, and some travel-related exposure to tick-borne microbes may be present. 
Another potential weakness is possible selection biases due to our recruitment method. 
However, there was no significant differences in seroprevalence of IgG antibodies to Bbsl 
between those recruited when attending the general practitioner’s center, those recruited by 
invitation, and those with other/unknown way of recruitment (participants were asked about 
way of recruitment in the questionnaire, and classified as “unknown way of recruitment” if 
the question was not answered). The recruitment rate was lower among the younger age 
groups, and lower among males than females. Of the seroprevalences to the different tick-
borne microbes, only the seroprevalence of antibodies to Bbsl showed a clear gender and age 
related association, and this was adjusted for when estimating the overall seroprevalence of 
IgG antibodies to Bbsl among the Søgne population aged 18-69 years (estimated to 19.5% vs 
22.0% among all the study participants). The seroprevalence of IgG antibodies to Bbsl did not 
differ significantly between the samples tested for at least one other pathogen than Bbsl and 
the samples tested only for Bbsl. We therefore consider the selection of samples tested for 
other microbes than Bbsl as representative with respect to exposure to tick-borne infections. 
In conclusion, our study indicates a high exposure to tick-bites and tick-borne microbes in the 
general adult population living in a coastline municipality in the southernmost part of 
Norway. The seroprevalence of IgG antibodies to Bbsl was high. Further, our study indicates 
that the population also is exposed to A.phagocytophilum, R. helvetica/R. conorii, B. microti 
and TBEV, but very rarely to B. henselae/B. quintana. In case of symptoms of infectious 
disease after a tick-bite, or fever without known cause, other tick-borne infections than Bbsl 
and TBEV should therefore be considered. However, serological testing should be interpreted 
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Males 1674 44.0 














































One tick-bite  366 12.4 
Two tick-bites  259 8.8 
Three or more tick-bites  1883 63.9 
Tick-bite in the last year 984 33.4 
Erythema migrans  723 24.6 
Neuroborreliosis  
Borrelia arthritis 
Tick-borne encephalitis  
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IgG equivocal 
% (95% CI) 
 
IgG negative 
% (95% CI) 
 
 









Tick-borne encephalitis virus 1453 3.1 (2.2-4.0) 0.6 (0.2-1.0) 96.3 (95.3-97.3) 
Anaplasma phagocytophilum 1452 11.0 (9.3-12.6) 6.1 (4.9-7.4) 82.9 (81.0-84.9) 
Babesia microti 1537 2.1 (1.4-2.9) 3.2 (2.3-4.1) 94.7 (93.5-95.8) 
Bartonella henselae or/and B. quintana 1451 0.1 (-0.1-0.3) 1.7 (1.1-2.4) 98.2 (97.4-98.8) 
Rickettsia helvetica or/and R. conorii 1445 4.2 (3.1-5.2) 5.1 (3.9-6.2) 90.8 (89.3-92.3) 
 
 


























Males and females 














 11.9 (8.6-15.2) 
30-39 47 18.8 (14.0-23.6) 40  11.6 (8.2-15.0) 87 14.6 (11.8-17.5) 
40-49 92 23.0 (18.9-27.1) 61  12.8 (9.8-15.9) 153 17.5 (15.0-20.0) 
50-59 117 27.7 (23.5-32.0) 81 20.1 (16.2-24.0) 198 24.0 (21.1-26.9) 
60-69 187 42.1 (37.5-46.7) 116 25.2 (21.2-29.1) 303 33.5 (30.4-36.6) 
18-69 
 
463 27.7 (25.5-29.8) 322 17.0 (15.3-18.7) 785 22.0 (20.6-23.4) 
 













Table 5: Prevalence of serum IgG antibodies to other tick-borne microbes among individuals with and without 
antibodies to Borrelia burgdorferi sensu lato  
 
  







Babesia Bartonella Rickettsia 
 











Borrelia IgG negative or equivocal  3.2 (36/1130)  9.8 (111/1130) 1.8 (22/1197) 0.2 (2/1128) 3.5 (39/1122) 
P-value 
 
0.715 0.010 0.117 1.000 0.016 
 
Abbreviations: Borrelia: Borrelia burgdorferi sensu lato, TBEV: Tick-borne encephalitis virus, Anaplasma: Anaplasma 
phagocytophilum, Babesia: Babesia microti, Bartonella: Bartonella henselae or/and B. quintana, Rickettsia: Rickettsia helvetica 
or/and R. conorii. 
 
 
 
 
 
 
 
 
 
 
 
 
